title: Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study.
abstract: OBJECTIVE
  Bariatric surgical treatments have been proven to induce long-term weight loss in morbidly obese patients, but complications are relatively frequent. We recently reported a first human multicenter trial assessing the safety, feasibility, and weight loss results of the Transoral Gastroplasty (TOGA) system (Satiety Inc., Palo Alto, CA) at 6 months. Here we report the 6-month results of the second phase of the pilot trial with the TOGA system, with technical improvements to the device.
  
  
  METHODS
  Patients met established criteria for bariatric surgery. The TOGA system, a set of transoral endoscopically guided staplers, was used to create a stapled restrictive pouch along the lesser curvature of the stomach. Follow-up was at 1 week and at 1, 3, and 6 months. At 3 months, re-treatment consisting in additional distal restrictions was allowed if necessary.
  
  
  RESULTS
  Data were available for 11 patients in our center (7 female, mean age 44.2 years, mean body mass index 41.6). The procedure was completed safely in all patients. There were no serious adverse events. Mean excess weight loss was 19.2 %, 33.7 %, and 46.0 % at 1, 3, and 6 months, respectively. Average body mass index decreased from 41.6 before treatment to 33.1 at 6 months. Absolute mean weight loss was 9.9 kg, 17.5 kg, and 24.0 kg at 1, 3, and 6 months, respectively. A dramatic improvement in quality-of-life measures was observed in all patients.
  
  
  CONCLUSIONS
  This second pilot trial confirmed the feasibility and safety of transoral gastroplasty. The early results and technical improvements reported in the present study are encouraging in terms of safety, early weight loss, and quality of life, and clearly allowed multicenter trials, which are planned to start soon.
authors.affiliation: Department of Gastroenterology and Hepatopancreatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. christophe.moreno@erasme.ulb.ac.be
authors.forename: C
authors.initials: C
authors.lastname: Moreno
authors.forename: J
authors.initials: J
authors.lastname: Closset
authors.forename: S
authors.initials: S
authors.lastname: Dugardeyn
authors.forename: M
authors.initials: M
authors.lastname: Baréa
authors.forename: A
authors.initials: A
authors.lastname: Mehdi
authors.forename: L
authors.initials: L
authors.lastname: Collignon
authors.forename: M
authors.initials: M
authors.lastname: Zalcman
authors.forename: M
authors.initials: M
authors.lastname: Baurain
authors.forename: O
authors.initials: O
authors.lastname: Le Moine
authors.forename: J
authors.initials: J
authors.lastname: Devière
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D016145:Endoscopy, Digestive System; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D015391:Gastroplasty / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009767:Obesity, Morbid / Q000601:surgery*; D010865:Pilot Projects; D017792:Surgical Stapling / Q000379:methods*; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D000893:Anti-Inflammatory Agents